The Cancer Research Technology Program (CRTP) leads scientific initiatives and provides technical solutions to meet the challenges of and carry out mission-driven biomedical research.
A major research area for the program is the National Cancer Institute's RAS Initiative, established in 2013 to explore innovative approaches for attacking proteins encoded by mutant forms of the RAS family of genes. These flawed proteins underlie more than 30 percent of all human cancers, including 95 percent of pancreatic cancers and 45 percent of colorectal cancers. The long-term goal of the initiative is to create effective, new therapies for RAS-driven cancers.
The RAS Initiative continues to evolve around a hub-and-spoke model with the Frederick National Lab's Advanced Technology Research Facility in Frederick, Md. as the hub of activity and spokes reaching out to collaborators across the country among academic, commerical, nonprofit, and government scientists.
CRTP continues to lead and support nationally shared resources, such as those provided by the Antibody Characterization Laboratory (ACL) and Nanotechnology Characterization Laboratory.
- Quantification of the impact of the HIV-1 glycan shield on antibody elicitation
- A signaling checkpoint to suppress the Ras pathway during conditions of cellular stress
- Genetic alterations associated with prostate cancer may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease
- Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Program Areas and Laboratories
- Antibody Characterization Laboratory
- Nanotechnology Characterization Laboratory
- CCR Sequencing Facility
- Center for Cancer Research Dedicated Core Services
- Center for Molecular Microscopy